BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 25584860)

  • 1. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
    Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z
    Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X; Gu X; Wang H; Yang J; Mao S
    Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid.
    Tian Q; Wang XH; Wang W; Zhang CN; Wang P; Yuan Z
    Nanomedicine; 2012 Aug; 8(6):870-9. PubMed ID: 22100756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
    Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
    Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycyrrhetinic acid-cyclodextrin grafted pullulan nanoparticles loaded doxorubicin as a liver targeted delivery carrier.
    Yang W; Zhang Y; Wang J; Li H; Yang H
    Int J Biol Macromol; 2022 Sep; 216():789-798. PubMed ID: 35914549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy.
    Wang FZ; Xing L; Tang ZH; Lu JJ; Cui PF; Qiao JB; Jiang L; Jiang HL; Zong L
    Mol Pharm; 2016 Apr; 13(4):1298-307. PubMed ID: 26894988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer.
    Zhang Y; Cui Z; Mei H; Xu J; Zhou T; Cheng F; Wang K
    Carbohydr Polym; 2019 Sep; 219():143-154. PubMed ID: 31151511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
    Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
    Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
    J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy.
    Zhang J; Tao W; Chen Y; Chang D; Wang T; Zhang X; Mei L; Zeng X; Huang L
    J Mater Sci Mater Med; 2015 Apr; 26(4):165. PubMed ID: 25791459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H; Liu M; Yu A; Ji J; Zhai G
    Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
    Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
    Lee JY; Chung SJ; Cho HJ; Kim DD
    Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.